论文部分内容阅读
目的分析拉米夫定联合阿德福韦酯治疗活动性乙型肝炎肝硬化的临床疗效。方法选取2010年1月~2012年9月活动性乙型肝炎肝硬化患者243例,按治疗方法将其分为观察组(n=123)与对照组(n=120)。对照组患者给予拉米夫定口服治疗;观察组患者在对照组治疗基础上加用阿德福韦酯进行治疗,2组患者治疗48周后,将2组患者的HBV DNA转阴率及肝纤维化指标检测值进行对比。结果观察组患者的HBV DNA转阴率明显高于对照组,差异有统计学意义(P<0.05);观察组患者的肝纤维化指标检测值明显低于对照组,差异有统计学意义(P<0.05)。结论将拉米夫定与阿德福韦酯联合应用于活动性乙型肝炎肝硬化患者的治疗中,治疗效果较明显,能够逆转肝纤维病理化改变,有效保护肝脏细胞,延缓患者病情的进展。
Objective To analyze the clinical efficacy of lamivudine combined with adefovir dipivoxil in the treatment of active hepatitis B cirrhosis. Methods Totally 243 patients with active hepatitis B cirrhosis from January 2010 to September 2012 were divided into observation group (n = 123) and control group (n = 120) according to the treatment method. The patients in the control group were treated with lamivudine orally. The patients in the observation group were treated with adefovir dipivoxil on the basis of the control group. After 48 weeks of treatment, the HBV DNA negative rate and liver Fibrosis index test values were compared. Results The negative rate of HBV DNA in observation group was significantly higher than that in control group (P <0.05), and the detection value of liver fibrosis index in observation group was significantly lower than that in control group (P <0.05). Conclusion Lamivudine combined with adefovir dipivoxil in active hepatitis B patients with liver cirrhosis treatment, the treatment effect is more obvious, can reverse the pathological changes of liver fibrosis, effectively protect the liver cells, delay the progress of the patient’s condition .